Top Page
Beauty Farm Medical & Health Industry, Inc.
(2373)
Beauty Farm Medical & Health Industry, Inc. (2373) vs. iShares MSCI Hong Kong ETF (EWH)
Beauty Farm Medical & Health Industry, Inc. Business Overview & Revenue Model
Beauty Farm Medical & Health Industry, Inc. Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 2.89B | 2.57B | 2.15B | 1.64B | 1.78B | 1.50B |
| Gross Profit | 1.38B | 1.19B | 977.10M | 717.84M | 833.79M | 700.02M |
| EBITDA | 497.57M | 427.49M | 644.82M | 452.43M | 554.51M | 473.71M |
| Net Income | 268.72M | 228.46M | 215.66M | 103.11M | 193.47M | 150.96M |
Balance Sheet | ||||||
| Total Assets | 4.31B | 4.28B | 3.30B | 2.50B | 2.48B | 2.10B |
| Cash, Cash Equivalents and Short-Term Investments | 2.00B | 1.83B | 1.57B | 910.63M | 1.08B | 801.92M |
| Total Debt | 779.08M | 730.59M | 563.12M | 525.50M | 515.46M | 515.69M |
| Total Liabilities | 3.38B | 3.30B | 2.47B | 2.29B | 2.21B | 1.96B |
| Stockholders Equity | 881.02M | 944.64M | 801.90M | 188.75M | 257.36M | 140.87M |
Cash Flow | ||||||
| Free Cash Flow | 1.04B | 682.44M | 466.27M | 241.21M | 536.76M | 613.03M |
| Operating Cash Flow | 984.28M | 796.63M | 625.51M | 382.00M | 669.93M | 680.53M |
| Investing Cash Flow | -394.38M | -340.85M | -711.18M | 53.63M | -385.35M | -368.94M |
| Financing Cash Flow | -325.44M | -223.36M | 133.74M | -432.82M | -271.06M | -273.33M |
Beauty Farm Medical & Health Industry, Inc. Technical Analysis
Beauty Farm Medical & Health Industry, Inc. Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
66 Neutral | HK$7.63B | 25.99 | 31.23% | 1.69% | 28.53% | 22.34% | |
66 Neutral | HK$1.59B | 5.48 | 20.47% | 4.41% | -3.56% | -17.45% | |
65 Neutral | HK$6.92B | 18.60 | 14.86% | 2.57% | 16.41% | 32.97% | |
64 Neutral | HK$8.23B | 16.73 | 6.78% | ― | -13.92% | -36.32% | |
55 Neutral | HK$6.92B | ― | -9.67% | 2.35% | -8.56% | -403.12% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
42 Neutral | HK$61.84M | ― | -51.07% | ― | -20.66% | -77.84% |
Beauty Farm Medical & Health Industry, Inc. Corporate Events
Beauty Farm Medical and Health Industry Inc. announced a voluntary on-market share repurchase, acquiring 50,000 shares for approximately HK$1,565,530. The Board believes the current share price undervalues the company and sees the repurchase as a demonstration of confidence in its long-term value, aiming to enhance market value and shareholder returns.
The most recent analyst rating on (HK:2373) stock is a Hold with a HK$37.00 price target. To see the full list of analyst forecasts on Beauty Farm Medical & Health Industry, Inc. stock, see the HK:2373 Stock Forecast page.
Beauty Farm Medical and Health Industry Inc. announced a voluntary on-market share repurchase of 70,000 shares, totaling approximately HK$2,209,470, as part of a broader repurchase strategy that has seen 210,000 shares bought back since October 15, 2025. The board believes this move reflects confidence in the company’s long-term value and aims to enhance its market value and shareholder returns.
The most recent analyst rating on (HK:2373) stock is a Hold with a HK$37.00 price target. To see the full list of analyst forecasts on Beauty Farm Medical & Health Industry, Inc. stock, see the HK:2373 Stock Forecast page.
Beauty Farm Medical & Health Industry Inc. announced a voluntary on-market share repurchase, acquiring 60,000 shares for approximately HK$1,942,870, reflecting management’s confidence in the company’s long-term value. The board believes the current share price undervalues the company’s prospects, and this repurchase aims to enhance the company’s market value and shareholder returns.
The most recent analyst rating on (HK:2373) stock is a Hold with a HK$37.00 price target. To see the full list of analyst forecasts on Beauty Farm Medical & Health Industry, Inc. stock, see the HK:2373 Stock Forecast page.
Beauty Farm Medical and Health Industry Inc. announced a recent on-market share repurchase, acquiring 30,000 shares for approximately HK$1,011,030. The Board believes the current share price undervalues the company’s intrinsic worth and business prospects, and the repurchase reflects confidence in its long-term value, aiming to enhance market value and shareholder returns.
The most recent analyst rating on (HK:2373) stock is a Buy with a HK$30.00 price target. To see the full list of analyst forecasts on Beauty Farm Medical & Health Industry, Inc. stock, see the HK:2373 Stock Forecast page.
Beauty Farm Medical and Health Industry Inc. announced a voluntary on-market share repurchase of 50,000 shares at an average price of HK$33.90 per share, totaling approximately HK$1,694,810. The board believes this move reflects confidence in the company’s long-term value and aims to enhance its market value and shareholder returns. The repurchase was conducted under a mandate allowing the company to buy back up to 10% of its issued shares.
The most recent analyst rating on (HK:2373) stock is a Buy with a HK$30.00 price target. To see the full list of analyst forecasts on Beauty Farm Medical & Health Industry, Inc. stock, see the HK:2373 Stock Forecast page.
Beauty Farm Medical & Health Industry, Inc. has announced a major transaction involving the acquisition of 100% of the issued shares in Shanghai Siyanli Industrial for RMB1,250.0 million. This acquisition will result in Shanghai Siyanli Industrial becoming an indirect wholly-owned subsidiary of Beauty Farm, with its results, assets, and liabilities consolidated into the group’s accounts. The transaction involves the issuance of consideration shares, which will be subject to shareholder approval at an Extraordinary General Meeting (EGM). The acquisition is classified as a major transaction under the Listing Rules, necessitating certain reporting and approval requirements. Shareholders and potential investors are advised to exercise caution as the acquisition is subject to conditions precedent and may not proceed.
The most recent analyst rating on (HK:2373) stock is a Buy with a HK$30.00 price target. To see the full list of analyst forecasts on Beauty Farm Medical & Health Industry, Inc. stock, see the HK:2373 Stock Forecast page.
Beauty Farm Medical & Health Industry Inc. announced its interim results for the first half of 2025, showcasing significant growth in key financial metrics. The company reported a 28.2% increase in revenue and a 35.5% rise in net profit compared to the same period in 2024, driven by a substantial increase in client visits and active members at its direct stores. The gross profit margin improved to 49.3%, reflecting enhanced operational efficiency. The company also provided non-HKFRS adjusted net profit figures, highlighting a 37.8% increase, which offers additional insights into its financial performance. These results underscore the company’s strong market positioning and operational success, benefiting shareholders and potential investors.
The most recent analyst rating on (HK:2373) stock is a Buy with a HK$30.00 price target. To see the full list of analyst forecasts on Beauty Farm Medical & Health Industry, Inc. stock, see the HK:2373 Stock Forecast page.
Beauty Farm Medical & Health Industry, Inc. has announced the composition of its board of directors, detailing the roles and functions of each member. This announcement may influence the company’s governance and strategic direction, potentially impacting its market positioning and stakeholder relations.
Beauty Farm Medical & Health Industry Inc. announced the completion of a significant share disposal by CITIC Private Equity Funds Management Co., Ltd., which is no longer a substantial shareholder. This transition has led to a more stable equity structure, improved corporate governance, and increased market liquidity, with new long-term investors bringing strategic resources and international perspectives. Additionally, the company has undergone changes in its board of directors, with the resignation of two non-executive directors and the appointment of new directors, enhancing its leadership structure.
Beauty Farm Medical and Health Industry Inc. has announced that its board of directors will meet on August 26, 2025, to approve and publish the interim results for the first half of the year ending June 30, 2025. The company will also consider the payment of an interim dividend during this meeting. An earnings conference call will be hosted on the same day to discuss these results and address any inquiries from stakeholders. This announcement is significant as it provides insights into the company’s financial performance and potential dividend payouts, which are crucial for investors and stakeholders.
Beauty Farm Medical & Health Industry Inc. has announced a series of subscriptions to wealth management products through Tianjin Heping with CITIC Bank, totaling RMB260 million. These subscriptions, aimed at making efficient use of idle funds, are aggregated as a discloseable transaction under Hong Kong’s Listing Rules due to their cumulative percentage ratios exceeding 5%, thus requiring notification and announcement.